UC San Diego

UC San Diego Previously Published Works

Title

WHO global research priorities for antimicrobial resistance in human health.

Permalink

https://escholarship.org/uc/item/9tg2d65s

Journal The Lancet Microbe, 5(11)

Authors

Bertagnolio, Silvia Dobreva, Zlatina Centner, Chad <u>et al.</u>

Publication Date

2024-11-01

DOI

10.1016/S2666-5247(24)00134-4

Peer reviewed

Review

WHO global research priorities for antimicrobial resistance in human health

Silvia Bertagnolio, Zlatina Dobreva, Chad M Centner, Ioana Diana Olaru, Daniele Donà, Stefano Burzo, Benedikt D Huttner, Antoine Chaillon, Nebiat Gebreselassie, Teodora Wi, Mateusz Hasso-Agopsowicz, Benedetta Allegranzi, Hatim Sati, Verica Ivanovska, Kavita U Kothari, Hanan H Balkhy, Alessandro Cassini, Raph L Hamers, Kitty Van Weezenbeek, on behalf of the WHO Research Agenda for AMR in Human Health Collaborators

The WHO research agenda for antimicrobial resistance (AMR) in human health has identified 40 research priorities to be addressed by the year 2030. These priorities focus on bacterial and fungal pathogens of crucial importance in addressing AMR, including drug-resistant pathogens causing tuberculosis. These research priorities encompass the entire people-centred journey, covering prevention, diagnosis, and treatment of antimicrobial-resistant infections, in addition to addressing the overarching knowledge gaps in AMR epidemiology, burden and drivers, policies and regulations, and awareness and education. The research priorities were identified through a multistage process, starting with a comprehensive scoping review of knowledge gaps, with expert inputs gathered through a survey and open call. The priority setting involved a rigorous modified Child Health and Nutrition Research Initiative approach, ensuring global representation and applicability of the findings. The ultimate goal of this research agenda is to encourage research and investment in the generation of evidence to better understand AMR dynamics and facilitate policy translation for reducing the burden and consequences of AMR.

Introduction

Antimicrobial resistance (AMR) is a global public health hazard with serious economic consequences.^{1,2} To mitigate the effects of AMR, the WHO member states endorsed a global action plan on AMR in the year 2015, mandating WHO to develop a global public health research agenda for filling major gaps in the knowledge on AMR and monitoring its implementation.³

To facilitate evidence generation regarding the pathogens posing the greatest public health threat associated with AMR, WHO published the priority list of bacterial pathogens⁴ in 2017 and of fungal pathogens⁵ in 2022 and updated the priority list of bacterial pathogens⁶ in 2024. In addition, WHO regularly analyses the pipeline for agents that target bacteria and fungi to facilitate priority setting and inform research and development (R&D) efforts.⁷

Despite the increasing focus on AMR research, substantial knowledge gaps continue to hamper an effective response against AMR, as illustrated by the stagnant progress in the implementation of national action plans on AMR,⁸ particularly in low-income and middle-income countries (LMICs), which carry the highest burden of bacterial AMR.^{1,2} Large data gaps in the prevalence and burden of disease hinder reliable estimates of AMR, particularly in settings with inadequate laboratory capacity and data collection systems.

The pressing need for evidence to inform public health policy, one of WHO's strategic and operational priorities to address drug-resistant bacterial infections⁹ between the years 2025 and 2035, was recognised by the 77th World Health Assembly in a resolution on accelerating national and global responses to AMR.¹⁰ Approved on May 30, 2024, the resolution¹¹ urges the WHO member states to support and foster basic, applied, and implementation research on infection prevention and control, vaccines, diagnostic tools, therapeutics, and antimicrobial stewardship through

collaboration with academia, civil society, and the private sector.

Although research agendas have been successfully developed in other public health areas,¹²⁻¹⁴ initiatives aimed at bridging gaps in the research on drug-resistant bacterial infections in human health have fallen short of identifying key research priorities owing to the complex, multifaceted nature of AMR.^{15,16} Some initiatives focused solely on specific aspects of AMR^{15,17-20} or exclusively on the One Health interface,²¹ and priorities specifically relevant to low-resource settings were generally overlooked.

A prioritised, multidisciplinary research agenda on AMR is warranted to direct investments of governments and other research funders and to channel the attention of policy makers, researchers, and the private sector towards crucial knowledge gaps that demand evidence generation, which, in turn, could inform the development and effective implementation of AMR policies and interventions. We hereby present the first comprehensive effort focusing on infections caused by drug-resistant bacteria and fungi, developed with a robust and validated methodology for research prioritisation.

The WHO research agenda for AMR in human health

The research agenda aims to identify the most pressing global research priorities directly related to human health and with the greatest potential to influence policies, interventions, and tools to address AMR in fungal and bacterial priority pathogens identified by WHO, including drug-resistant *Mycobacterium tuberculosis*²² and *Mycoplasma genitalium* (panel 1).

The research agenda places particular emphasis on bridging the crucial knowledge gaps by the year 2030, in alignment with the global Sustainable Development Goals, and on research relevant for low-resource settings, in





Lancet Microbe 2024;5: 100902

Published Online August 13, 2024 https://doi.org/10.1016/ S2666-5247(24)00134-4

Antimicrobial Resistance Division (S Bertagnolio MD, Z Dobreva MSc, C M Centner MSc, S Burzo PhD, B D Huttner MD, A Chaillon MD, H Sati MD, V Ivanovska PhD, H H Balkhy MD, K V Weezenbeek PhD), Global Tuberculosis Programme (N Gebreselassie PhD), Global HIV, Hepatitis and STI Programme (T Wi MD), Department of Immunization, Vaccines & Biologicals

(M Hasso-Agopsowicz PhD), and Department of Integrated Health Services (B Allegranzi MD), WHO, Geneva, Switzerland; Department of Clinical Research. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK (I D Olaru PhD); Institute of Medical Microbiology, University of Münster, Münster, Germany (I D Olaru): Division of Paediatric Infectious Diseases, Department for Women's and Children's Health, University of Padua, Padua, Italy (D Donà PhD); Library and Digital Information Networks, WHO, Kobe, Japan (K U Kothari MPH): Public Health Department. Canton of Vaud, Lausanne, Switzerland (A Cassini MD): Infectious Diseases Service. Lausanne University Hospital, Lausanne, Switzerland (A Cassini); Oxford University Clinical Research Unit Indonesia. Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia (R L Hamers PhD); Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK (R L Hamers)

Correspondence to: Dr Silvia Bertagnolio, Antimicrobial Resistance Division, WHO, Geneva CH-1211, Switzerland **bertagnolios@who.int**

Panel 1: Research agenda development framework

Objectives

The research agenda has two objectives: to advance research on antimicrobial resistance (AMR) through identification and prioritisation of research topics encompassing the prevention, diagnosis, treatment and care, and burden and drivers of AMR and optimising intervention delivery; and to encourage increased investment and scientific interest among researchers, donors, and public health professionals.

Scope and focus

The research agenda is global in its scope and focuses on AMR in the human health sector, specifically infections caused by WHO bacterial and fungal priority pathogens of crucial importance for AMR and drug-resistant *Mycobacterium tuberculosis* and *Mycoplasma genitalium*. Other pathogens such as drug-resistant viruses and parasites are beyond the scope of the framework.

Population

The research agenda aims to define priorities for research applicable to the general population, including neonates and children.

Geographical context

Although global in scope, the research agenda places a particular focus on identifying knowledge gaps and prioritising research topics relevant for low-resource settings.

Timeframe

The research agenda aims to align its timeline with the Sustainable Development Goals, recognising the 2030 deadline for achieving both these global targets, and to address prioritised research topics.

Research investment strategy

The research agenda aims for investments in AMR research to be balanced and diversified across the prioritised research topics (ie, not focusing on one or a few high-risk or expensive research ideas or both) and encompassing the four domains of research (ie, descriptive, delivery, discovery, and development).

recognition of the disparities in accessibility, availability, and utilisation of diagnostics, antimicrobials, and measures for prevention of infection. The research agenda encompasses four research domains—description, delivery, development, and discovery research^{12,13,23}—and 11 AMR areas to comprehensively address the multifaceted challenges posed by AMR to human health. The development process of the research agenda (figure 1) encompasses four steps: preparatory phase, scoping review, consolidation of research topics (ie, survey 1), and research prioritisation (ie, survey 2).

Preparatory phase: defining governance, objectives, scope, methods, and establishment of the expert group

A multidisciplinary WHO steering group was established to oversee the entire development process, including defining the objectives, scope, population, geographical focus, timeframe, AMR areas, and prioritisation criteria.

We adopted the widely used priority-setting method known as the Child Health and Nutrition Research Initiative (CHNRI).^{12,13,23} This expert survey-based scoring system offers a systematic, transparent, and reproducible approach for prioritising research topics from a large pool of topics by a large group of experts. CHNRI offers an advantage over consensus-based approaches by mitigating individual opinion bias through independent scoring (panel 2).^{23,24}

A group of global experts was established through a combination of systematic Web of Science searches and referrals (appendix pp 2–5), seeking a diverse range of expertise across research domains, AMR areas, geographical representation, income settings, and populations. Among the 560 experts identified, 261 (47%) contributed to the development of the research agenda (survey 1, survey 2,

or both). Experts were from 69 countries across all WHO regions—European region (41%), region of the Americas (24%), African region (15%), Western Pacific region (8%), South-East Asia region (7%), and Eastern Mediterranean region (4%)—with the highest representation from the UK, USA, South Africa, Switzerland, Canada, India, Brazil, and Australia (figure 2A).

Identifying knowledge gaps and research topics: a scoping review

The initial CHNRI step entailed experts submitting research proposals or ideas. We augmented this step with a comprehensive scoping review of peer-reviewed and grey literature published in the preceding 10 years (2012-21) and included a comprehensive search for systematic and scoping reviews indexed in PubMed, Embase, and Web of Science, as well as manual searches of data repositories and websites of 92 key organisations. The detailed findings of the scoping review have been presented elsewhere.25,26 In brief, the review identified 2340 knowledge gaps (panel 3) sourced from a pool of over 3000 documents. The knowledge gaps covered the burden, drivers, technologies, tools, and interventions for the prevention, diagnosis, and treatment of infections caused by drug-resistant pathogens, as well as care of affected individuals within the scope of this research agenda. These knowledge gaps were subsequently categorised into research topics or subtopics, depending on the level of granularity offered. The topics were further arranged into the population, intervention or exposure, comparator, outcome (PICO/PECO) format and consolidated into 177 thematic research topics.^{25,26}

The research topics were then organised into a knowledge matrix to categorise each topic into the four CHNRI-defined

www.thelancet.com/microbe Vol 5 November 2024

research domains (descriptive, delivery, development, and discovery research)^{12,13} and three themes (prevention, diagnosis, and treatment and care) according to the WHO people-centred approach for AMR.²⁷

Consolidating the research topics: survey 1 and open consultation

Through an online survey (survey 1) conducted from Oct 10 to Nov 2, 2022, 156 experts provided their inputs on the 177 research topics identified through the scoping review (appendix p 5). For each topic, experts could choose to agree with its inclusion, suggest text improvements, or recommend removal under the conditions that the topic was deemed to have sufficient existing evidence, be unlikely to inform policies or interventions, or be unfeasible to design and execute a research study and generate evidence²⁷ by the year 2030. In addition, expert group members could suggest up to two additional topics meeting five criteria—ie, a new topic not covered already in the list; addressing a crucial knowledge gap; relevant to human health; relevant for informing policy; and feasible to generate evidence by the year 2030.

Each research topic in survey 1 received recommendations for removal from at least one expert, with a median of seven suggestions (range 1–34) per topic. Additionally, 158 new topics were proposed by 90 experts, and 54 experts offered suggestions for improvement in existing topics. In parallel, we launched an open call for expert contributions via the WHO website to engage the broader research community.²⁸ The open call enabled individuals to review existing topics, propose new ones, and evaluate the proposed topics on the basis of the specified criteria. This process led to 18 individuals suggesting the removal of 58 topics and proposing seven new topics.

In addition to the 177 research topics identified from the scoping review, proposals from 165 new topics came from both the expert survey and open call. The topics underwent a rigorous iterative review on the basis of a semistructured decision-making process, involving subject area experts in the WHO steering group to agree on acceptance or rejection. This process resulted in 110 scoping review topics and 65 new topics being retained, 100 topics (from the scoping review, survey, or open call) being removed, and 70 topics being reclassified as subtopics. 22 topics of similar nature (albeit providing a slightly different perspective on the same subject) were combined with existing topics into composite research topics, which would require various types of studies to address them effectively. The steering group evaluated the revised list and suggested an additional 25 topics. Discrepancies among the topics were resolved through face-to-face or online meetings or via email, resulting in a final consolidated list of 175 topics.

Prioritising the research topics: survey 2

In survey 2, conducted from Feb 16 to May 30, 2023, 234 experts assigned scores for the 175 consolidated research topics (appendix p 5). Notably, 129 of these




Figure 1: Identification of the 40 research priorities in the WHO agenda for research on antimicrobial resistance and human health

LMICs=low-income and middle-income countries.

experts had also participated in survey 1. The experts specified their primary perspective (high-income, low-income and middle-income, or all income settings) and age focus (adults, children, or all age groups). In scoring the topics, 93 (40%) of 234 applied an LMIC perspective, 86 (37%) considered all income settings, and the remaining 55 (23%) applied a high-income settings perspective. Additionally, 78 (33%) experts focused on adults only, 38 (16%) focused on neonates or children only, and 118 (50%) considered all age groups in their scoring. Among the 234 experts participating in survey 2, 114 (49%) identified as women and 84 (36%) were affiliated with institutions in LMICs. The number of

Panel 2: Approaches for agenda priority setting

Consensus-based approaches

Consensus-based approaches lead to priorities decided by means of group consensus.

Strengths: Priorities decided by means of group consensus, which improves acceptability

Weaknesses: Not strictly systematic; might result in obvious priorities without strong evidence; priorities might reflect the views and biases of only a few experts and, potentially, those who are more vocal in the discussions; not feasible for prioritisation of a large number of research topics

Examples: Combined approach matrix and priority-setting partnerships

Usage: More often used for national prioritisation exercises

Metric-based approaches

Metric-based approaches generate priorities on the basis of an algorithm that pools individual scoring of research questions.

Strengths: Systematic and repeatable; reduces the risk of an individual opinion dominating over others; more feasible for a larger number of stakeholders to participate and dampens down the dominance of a minority but vocal stakeholders

Weaknesses: Scoring can be demanding for participants; individuals can score in isolation and can limit opportunities for dialogue

Examples: Child Health and Nutrition Research Initiative and Delphi techniques

Usage: More suitable for global prioritisation exercises

experts by research disciplines and AMR expertise are shown in figure 2B, C.

The experts assessed each individual research topic against five criteria (panel 4) and assigned their responses as: yes (score, 1 point), no (score, 0 point), or do not know. Intermediate criterion scores for each topic were calculated by summing the scores for each criterion and dividing by the number of experts who scored that topic and criterion, excluding blank or do-not-know responses.12,13 We repeated this calculation with input exclusively from experts assigning scores on topics from the perspective of LMICs. We then calculated a research priority score (RPS) for each topic from both global and LMIC perspectives. The RPS was calculated as a weighted average of the five criterion scores, with feasibility by 2030 and health equity carrying a weight of 10% each and the remaining three criteria carrying a weight of 27% each. This weightage distribution, following the methodology described by Rudan and colleagues,13 acknowledges some heterogeneity in the scoring. Notably, the interpretation of criterion feasibility by the year 2030 might not be consistent among experts, as research endpoints could be interpreted as study initiation, completion, or publication. Similarly, the health equity criterion might not be uniformly applied and could be perceived to be too abstract and difficult to measure. The topics were ranked into two separate lists on the basis of the weighted RPS: one global (irrespective of income setting) and one considering responses solely from experts assessing topics from an LMIC setting perspective.

Overall, the median number of experts scoring each topic (across all five criteria) was 140 (range 102–183). Across all the 175 research topics, the median RPS was 0.85 (0.62-0.95), and 130 (74%) topics had an RPS of 0.80 or higher. For LMICs, the median RPS was 0.90 (0.70-0.97), with 162 (92%) topics having an RPS of 0.80 or higher.

Following the ranking of topics based on descending RPS, the highest-scoring topics within the top 20th percentile were evaluated for potential inclusion in the definitive priority list. This threshold was selected to ensure a manageable number of research priorities with representation across all AMR areas and resulted in 35 globally ranked topics and an additional list of 35 topics from an LMIC settings perspective. We merged duplicates among the 70 identified topics, resulting in 40 research priorities for inclusion in the research agenda, addressing both global and LMIC perspectives. The prioritisation results were shared with the WHO steering group and the expert group via email and presented at a WHO global webinar.

Overview of the research priorities

The 40 research priorities include seven priority topics focused on drug-resistant tuberculosis and 33 on drug-resistant bacterial and fungal infections. The bacterial and fungal priorities are divided into prevention (n=4), diagnosis (n=6), treatment and care (n=11), and overarching themes, including AMR epidemiology, burden, and drivers, awareness and education, and policies and regulations (n=12; panel 5).

Prevention

Under the theme of prevention, two research priorities on water, sanitation, and hygiene (WASH) address the need to investigate the implementation and effect of WASH-related interventions on the burden of AMR and antimicrobial prescription in community and health-care settings. The infection prevention and control priority focuses on identifying multimodal intervention strategies and evaluating the relative effect of their components. The research priority on immunisation highlights the need to evaluate the effects of vaccines on colonisation, infection with resistant




Figure 2: Details of experts involved

(A) Geographical distribution of experts. (B) Number of experts by research discipline (data missing for 15 experts). (C) Number of experts in each antimicrobial resistance area (experts could report more than one research discipline and area of experts).

Panel 3: Definitions

Knowledge gap

Knowledge gaps refer to areas with incomplete understanding, information, or data. Identifying research gaps helps to formulate relevant and pressing research questions.

Research topic

A research topic encompasses multiple research questions. Rather than focusing on a single inquiry, a research topic involves exploring various facets or aspects of a broader research area.

Research priority

Research priorities are specific research topics that are deemed particularly important or urgent to address. These priorities guide researchers, policy makers, and funding agencies in allocating resources and efforts to areas that would benefit the most from additional evidence or that contain the most substantial knowledge gaps.

Research domain

Four research domains often used by the Child Health and Nutrition Research Initiative knowledge matrix to categorise research topics:

- Descriptive (have greater understanding of antimicrobial resistance [AMR] burden and drivers)
- · Delivery (provide ways to deliver existing interventions with better quality)
- Development (improve existing interventions, reduce their costs, or optimise their implementation)
- Discovery (identify new interventions to prevent, treat, and diagnose AMR)

AMR theme

The research topics and priorities cover three themes—AMR prevention, diagnosis, and treatment and care—in accordance with the WHO people-centred approach for addressing AMR, in addition to an overarching theme covering AMR epidemiology, burden and drivers, awareness and education, and policies and regulations.

AMR area

The research topics and priorities encompass areas relevant to AMR: water, sanitation, and hygiene; infection prevention and control; immunisation; diagnosis or diagnostics; antimicrobial stewardship; antimicrobial use; antimicrobial medicines; epidemiology, burden, and drivers of AMR; awareness and education; policies and regulations; and prevention, diagnosis, and treatment of drug-resistant tuberculosis, as well as care of individuals with drug-resistant tuberculosis.

WHO steering group

A group of WHO staff with technical expertise across various AMR areas. This group defined the objectives and scope of the agenda, supported the consolidation of research topics, developed the criteria for prioritisation, and guided the prioritisation process.

Expert group

A group of global experts external to WHO identified by means of a systematic search of publication output in Web of Science and referrals, with a mix of expertise from across research disciplines and AMR areas, geographical representation, income settings, and paediatric expertise. The expert group participated in the identification of knowledge gaps (survey 1) and prioritisation of research topics (survey 2).

Panel 4: Criteria for scoring and prioritising research topics

Filling crucial knowledge gaps

Is the research most likely to fill crucial knowledge gaps on antimicrobial resistance (AMR)?

Answerability and feasibility by the year 2030

Can a research study be designed and carried out by the year 2030 to address at least some components of the research topic? (Funding considerations should be disregarded.)

Potential for translation into policy

Do the findings have the potential to inform evidence-based policy and practices aimed at mitigating the effects of AMR on public health?

Effect on mitigating AMR

Is the research most likely to result in an intervention that is effective, efficacious, or efficient or combinations of these in mitigating the effects of AMR? (Effective: producing a desired effect in a real-world environment; efficacious: providing a desired effect in a controlled environment; efficient: providing highest value for the available resources.)

Promoting health equity

Is the research most likely to promote health equity (ie, leading to interventions that will reduce the inequitable effects of AMR across diverse socioeconomic contexts and underprivileged populations)?

Panel 5: 40 research priorities for antimicrobial resistance in human health across five themes and 11 areas, with research priority scores [RPSs] (the order in which research priorities are presented is unranked)

Prevention

Water, sanitation, and hygiene (WASH)

Investigate the effect, contribution, utility, effectiveness, and cost-effectiveness of interventions to ensure safe WASH (including hand hygiene) and waste management practices in the community setting on reducing the burden and drivers of antimicrobial resistance (AMR), such as unnecessary antibiotic use for diarrhoeal diseases in low-income and middle-income countries (LMICs; RPS=0.90*)

Investigate implementation strategies of WASH-related interventions in health-care settings (including ensuring access to safely managed water and sanitation, safe hand hygiene, and safe management of waste and environmental cleaning), and assess their effects, acceptability, equity, and cost-effectiveness on the burden and transmission of antimicrobial-resistant infections associated with health-care settings and prescription of antimicrobial drugs across socioeconomic settings (RPS=0.89*)

Infection prevention and control

Identify the most effective, cost-effective, acceptable, and feasible multimodal infection and prevention control strategies (such as hand hygiene, contact precautions, and patient isolation) and the relative effect of their components in reducing different types of infections associated with health-care settings caused by multidrug-resistant pathogens across geographical and socioeconomic settings (RPS=0-90*)

Immunisation

Assess the effect of vaccines on preventing colonisation and infection by drug-resistant pathogens (whether specifically targeted by the vaccine or not) and on reducing the overall use of antimicrobial drugs, and health-care encounters and health system costs among adults and children and across socioeconomic settings (RPS=0.94†)

Diagnosis

Diagnosis or diagnostics

Investigate and evaluate rapid point-of-care diagnostic tests (including biomarker-based tests) and diagnostic algorithms to distinguish between bacterial and viral infections and non-infectious syndromes that are feasible for use in low-resource settings and among different subpopulations (including children and neonates) and their effects on clinical outcomes (RPS=0.89*)

Investigate and evaluate diagnostic tests for isolating, identifying, testing the antimicrobial susceptibility, or detecting the resistance of bacterial pathogens, or any combination of these, including multiplex panel-based tests and tests using novel technologies that are fast, (near) point-of-care, affordable, feasible for use in low-resource settings and among different subpopulations and for various specimen types, and their effects on clinical outcomes (RPS=0.91*)

Investigate and evaluate phenotypic and genotypic methods of rapid antimicrobial susceptibility testing and resistance detection directly from positive blood culture bottles, especially for use in LMICs and their effects on clinical outcomes (RPS=0.89*)

Investigate and evaluate rapid, (near) point-of-care diagnostic tests (including antigen-based and multiplex panel-based tests) for detecting WHO fungal priority pathogens⁵ of crucial importance for AMR (such as *Candida auris, Aspergillus fumigatus,* and *Cryptococcus neoformans*) that are feasible for use in low-resource settings and among different subpopulations and their effects on clinical outcomes (RPS=0.89*)

Investigate and evaluate the clinical utility and diagnostic accuracy of phenotypic antifungal susceptibility testing (including identifying minimal inhibitory concentration breakpoints and testing for in-vitro synergy and in-vivo synergy between antifungal drugs) and its effects on clinical outcomes (RPS=0.94†)

Investigate, assess the performance, and evaluate the implementation of novel rapid point-of-care molecular and non-molecular assays, and optimal testing and screening approaches (including self-testing) for *Neisseria gonorrhoeae* and AMR detection, to reduce inappropriate prescription of antibiotics and emergence of AMR (RPS=0.90*)

Treatment and care

Antimicrobial stewardship

Investigate context-specific, feasible, sustainable, effective, and cost-effective antimicrobial stewardship interventions (such as implementing WHO access, watch and reserve [AWaRe] antibiotic book,²⁷ guidelines, clinical algorithms, education and training, audit, and feedback), alone or in combination, to avoid antimicrobial misuse in outpatient and inpatient settings, especially under situations with inadequate diagnostic capacity (RPS=0.95*)

Identify feasible, effective, and scalable pharmacist antimicrobial drugs-dispensing practices and related regulatory frameworks to improve antimicrobial stewardship in the community, especially in LMICs (RPS=0.90*)

Investigate criteria and strategies to optimise empirical antimicrobial therapy for important infectious syndromes, such as bloodstream, upper and lower respiratory tract, urinary tract, skin and soft tissue, CNS, and sexually transmitted infections, especially in settings with inadequate medicine availability, diagnostic capacity, and access to health-care services (RPS=0.92*)

Antimicrobial use‡

Identify optimal (feasible, accurate, and cost-effective) methods and metrics to monitor antimicrobial use in the community and health-care settings and appropriate targets to monitor progress in reducing inappropriate antimicrobial use (RPS=0.88*)

Determine the levels, patterns, trends, and drivers of appropriate and inappropriate prescribing of AWaRe antibiotics²⁹ across countries and community and health-care settings, with data disaggregated on the basis of sex, age, socioeconomic status and subpopulations, including those that are experiencing vulnerability $(RPS=0.91^{*})$

Investigate optimal approaches to effectively use facility-level, national-level, or their combination antimicrobial use and resistance surveillance data to inform antimicrobial stewardship programmes and treatment guidelines (RPS=0.91*)

Antimicrobial medicines

Investigate efficacious and safe antibiotic treatment regimens for infections on the basis of old and new agents (and their combinations), especially those of extendedspectrum β -lactamase-producing or carbapenem-resistant Enterobacterales, or both, with minimum selection and transmission risk for AMR, especially among children and other clinically vulnerable subpopulations (RPS=0.90*)

Investigate efficacious and safe antibiotic treatment regimens for infections by drug-resistant typhoid and non-typhoidal salmonella (including pathogens resistant to cephalosporins and fluoroquinolones) across socioeconomic settings (RPS=0-93†)

Investigate efficacious and safe empirical antibiotic treatment (drug choice, drug combination, route, dose, and duration) for Gram-negative bacteria causing bloodstream infections or sepsis among neonates and young children, especially in settings with high AMR prevalence and inadequate diagnostic capacity and antimicrobial drug availability (RPS=0.90*)

Investigate antifungal regimens optimised for efficacy, cost, safety, and duration for the treatment of infections caused by WHO fungal priority pathogens⁵ of crucial importance for AMR (such as *C auris*, *A fumigatus*, and *C neoformans*) in settings with increasing or high prevalence of antifungal resistance (RPS= 0.89^*)

Investigate efficacious and safe regimens on the basis of new or existing antimicrobial medicines for urogenital and extragenital sexually transmitted infections (such as drug-resistant *N gonorrhoeae* or *Mycoplasma genitalium*) in the context of increasing AMR levels, including in populations experiencing vulnerability (RPS=0.89*)

Overarching topics

AMR epidemiology, burden, and drivers

Investigate the prevalence, incidence, mortality, morbidity, and socioeconomic effects of community-acquired infections (respiratory tract, urinary tract, and bloodstream infections) and infections associated with health-care settings (bloodstream, urinary tract, surgical site, and respiratory tract infections) by resistant WHO bacterial priority pathogens (*Acinetobacter baumannii*, *Pseudomonas aeruginosa*, Enterobacterales, *Enterococcus faecium*, *Staphylococcus aureus*, *Helicobacter pylori*, *Campylobacter* spp, *Salmonella* spp, *N gonorrhoeae*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Shigella* spp),⁴ with data disaggregated on the basis of sex, age, socioeconomic status, and in subpopulations experiencing vulnerability§ and across socioeconomic settings, especially in LMICs (RPS=0·91*)

Investigate the prevalence, incidence, morbidity, mortality, and socioeconomic effects, and identify and quantify the routes and dynamics of infections by drug-resistant WHO fungal priority pathogens⁵ of crucial importance for AMR (such as *C auris*, *A fumigatus*, and *C neoformans*), across geographical and socioeconomic settings and in populations experiencing vulnerability (RPS=0.94)

Investigate the association, contribution, and effects of structural and health system factors (such as hospital microbiome, sanitation infrastructure, waste management, health expenditure, governance, distribution of resources, population displacement, conflict, and disruptions in the care continuum) on colonisation (selection, persistence, and spread or loss of bacterial populations) and infection by WHO bacterial⁴ and fungal⁵ priority pathogens in various subpopulations, including those experiencing vulnerability§ and people with comorbidities, across various socioeconomic settings (RPS=0.94*)

Identify optimal (efficient, effective, and cost-effective) surveillance methods to generate accurate and reliable data on the epidemiology and burden of AMR among WHO bacterial⁴ and fungal⁵ priority pathogens (including identifying the genotypic predictors of resistance) in community and health-care settings and disaggregated on the basis of sex, age, and subpopulations; moreover, these data should be relevant and actionable at the local and national levels, especially in LMICs (RPS=0·94^{*})

Assess the short-term and long-term effects of the programmatic use of antimicrobial drugs in mass administration on AMR, focusing on clinically susceptible subpopulations in low-income settings (RPS=0.90*)

Evaluate the public health benefits, cost, and effects on unnecessary or inappropriate prescription of antibiotics, and potential AMR consequences of currently recommended syndromic sexually transmitted infection management and treatment of individuals with asymptomatic sexually transmitted infections (including *N gonorrhoeae* infection) in settings with variable diagnostic capacity (RPS=0.95†)

AMR awareness and education

Identify the most cost-effective behavioural change interventions to mitigate the emergence and spread of AMR by targeting and engaging the general public, young people, mass media, health-care providers, and policy makers across socioeconomic settings (RPS=0.94*)

Policies and regulations related to AMR

Evaluate the implementation of AMR-related policies and regulations at the national level and their effectiveness in mitigating AMR and improving health outcomes in the community and health-care settings across socioeconomic settings (RPS=0.93⁺)

Investigate strategies for the sustainable and cost-effective implementation of national policies, legislation, and regulations (including sustainable financing and optimal governance structures) to improve infection prevention and patient care practices and the use of antimicrobial drugs in the community and health-care settings, across socioeconomic settings (RPS=0.89*)

Identify the most cost-effective interventions to mitigate AMR in the human health sector, globally and within countries or regions, and identify the rationale, costs, benefits, feasibility, sustainability, and potential returns on investment to achieve the greatest benefit (RPS=0.89*)

Investigate strategies to integrate AMR interventions into broader health, health financing, development, welfare structures and national policies, and evaluate their effects on mitigating AMR, enhancing health system efficiency, reducing people's out-of-pocket expenses, and improving equitable access to and use of diagnostics and antimicrobial drugs (RPS=0.96†)

Investigate how existing regulatory frameworks, marketing incentives (or their absence), and sustainable financing models affect the development and availability of new antimicrobial drugs and identify effective strategies to adapt these approaches to low-income settings to improve their availability for adults and children (RPS=0.96†)

Drug-resistant tuberculosis

Prevention

Investigate effective preventive tuberculosis vaccines that meet the criteria of WHO-preferred product characteristics and show effects on preventing infection, disease, and recurrence (relapse or reinfection), thereby preventing or reducing the incidence of drug-resistant tuberculosis (RPS=0.89*)

Diagnosis

Investigate how the diagnostic performance of molecular assays can be improved to detect drug resistance among individuals with extrapulmonary and pulmonary tuberculosis caused by non-respiratory specimens, including among children and adolescents (RPS=0.94†)

Identify optimal diagnostic and treatment delivery models to improve the access, effectiveness, cost-effectiveness, feasibility, and acceptability of drug-resistant tuberculosis testing and treatment across settings and subpopulations experiencing vulnerability§ (such as people living with HIV, children and adolescents, and prisoners) and evaluate their effects on reducing drug-resistant tuberculosis at the population level (RPS=0.90*)

Treatment and care

Investigate better tolerated, optimally dosed, more effective, and shorter combination regimens using a stratified risk approach for treating all forms of drug-resistant tuberculosis, including in socioeconomically or clinically vulnerable populations (RPS=0.92*)

Identify the optimal, cost-effective, shortest duration, and safest tuberculosis-preventive treatment for the contacts of individuals with drug-resistant tuberculosis, especially among individuals at high risk of tuberculosis infection and disease, as identified in WHO guidance, and eligible clinically vulnerable or susceptible populations (such as children, adolescents, people living with HIV, and pregnant women; RPS=0.91*)

Investigate strategies for improving treatment outcomes among people with drug-resistant tuberculosis who have known risk factors and co-occurring conditions (such as HIV, undernutrition, diabetes, tobacco use, alcohol and other substance use, and mental health disorders) and clinically susceptible populations (such as pregnant and breastfeeding women, children and adolescents, and prisoners) in various geographical and socioeconomic settings (RPS=0.97†)

Investigate the programmatic effectiveness, safety, and tolerability of currently used WHO-recommended treatment regimens for drug-resistant tuberculosis (including combinations that contain bedaquiline and pretomanid or delamanid) on patient outcomes and the emergence of drug-resistant tuberculosis across populations and settings and identify the drivers of treatment failure (RPS=0-95†)

*RPS was within the top 20th percentile upon considering the responses of all experts. †RPS was within the top 20th percentile upon considering the responses of experts giving scores with a low-income and middleincome setting perspective only. ‡Antimicrobial use refers to antimicrobial use data (elsewhere referred as antimicrobial consumption data) that provide information on the quantity and types of antimicrobials used in the settings in which they are administered as well as clinical data linking antimicrobial use patterns, regimens, dose, route, duration, and indication with patient clinical characteristics. SPopulations that are experiencing socioeconomical and clinical vulnerability include children, pregnant women, breastfeeding mothers, people living in remote or rural settings, migrants, refugees, prisoners, and people experiencing tuberculosis or malaria and people living with HIV. Relevant populations might differ by topic.

organisms, and their indirect effects in strengthening stewardship efforts and reducing the prescription of antimicrobials.

Diagnosis

Under the theme of diagnosis, six priorities focus on better, accessible, and affordable diagnostics, including point-ofcare tests for distinguishing bacterial and viral infections and rapid phenotypic and molecular methods for bacterial identification and antimicrobial susceptibility testing. These topics reflect the stagnant progress in effective diagnosis, with nearly half of the world's population living with little or no access to diagnostics.³⁰ Two priorities focus on the need for better detection and susceptibility testing of WHO fungal priority pathogens of crucial importance for AMR.³¹ One priority addresses the need to better understand the performance of and approaches to implement point-of-care tests for *Neisseria gonorrhoeae*. These tests should contribute

to improved identification and management of individuals with potentially asymptomatic sexually transmitted infections, thus reducing transmission and unnecessary use of antibiotics and helping to identify the emergence and transmission of AMR.

Treatment and care

Under the theme of treatment, three priorities pertain to antimicrobial stewardship target interventions to minimise antimicrobial misuse and strategies to optimise empirical treatment. This emphasis is particularly important in settings with inadequate diagnostic capacity and access to health-care services. The research agenda emphasises the need for studies on pharmacy-level interventions and higher-level frameworks regulating antimicrobial dispensing to improve antimicrobial stewardship in primary care. Three priorities address the need to identify optimal methods and metrics for monitoring antimicrobial use and approaches to effectively use facility-level and national-level surveillance data on antimicrobial use to inform treatment guidelines and stewardship programmes. Five research priorities encompass the investigation of new and existing antimicrobials, with special emphasis on enhancing the treatment of drug-resistant Enterobacterales, including typhoidal and non-typhoidal salmonella. Furthermore, the research priorities focus on infections caused by sexually transmitted and fungal priority pathogens as well as bloodstream infections caused by Gram-negative bacteria in neonates and young children.32

Overarching topics

The availability of reliable AMR surveillance data, and therefore the understanding of AMR, can vary markedly between high-resource and low-resource settings.1 Six research priorities focus on understanding the epidemiology, burden, and drivers of drug-resistant bacterial and fungal pathogens and identifying optimal AMR surveillance methods for obtaining accurate and representative data. These research priorities are central for developing evidence-based treatment guidelines and measuring the success of interventions aimed at mitigating the emergence of drug resistance and transmission. Furthermore, the effect of addressing these research priorities on antimicrobial prescription and AMR needs to be investigated. An additional priority raises issues on the effects of programmatic use of antimicrobials in mass or targeted administration on the development of drug resistance and its persistence. The agenda recognises the importance of behavioural change interventions in mitigating AMR and identifying the interventions that might improve AMR awareness and education among both the public (including young people and through mass media) and health-care providers.

Five research priorities address policies and regulations related to AMR. Although studies have assessed the gaps and opportunities to strengthen national-level governance efforts and AMR national action plans,^{33,34} the agenda emphasises the need for context-specific evidence for formulation of effective strategies to implement national AMR policies and programmes and facilitate a more customised approach to policy implementation. The actions in low-resource settings are often based on evidence from high-income countries; however, knowledge gaps are especially evident in low-resource settings since the availability of resources, socioeconomic and political context, and cultural drivers of antimicrobial use differ between the two settings. Furthermore, information on cost-saving or cost-effective AMR interventions in both hospital and community settings would inform rational policy design. Although evidence from modelling studies in high-income settings exists, data from real-world observational studies and low-resource settings are scarce.35-37 Evidence-based strategies to effectively integrate AMR interventions into existing national health system structures, thereby avoiding a siloed AMR programme, are warranted to foster financial sustainability of the AMR response.

An important research priority is related to evaluation of the effect of regulatory frameworks, marketing incentives (including pull incentives), and sustainable financing models on antimicrobial R&D pipelines, considering that push incentives alone are deemed insufficient to ensure a healthy pipeline.^{38,39} Although countries such as Sweden and the UK have been experimenting with novel economic incentives,⁴⁰⁻⁴² ensuring equitable access to antimicrobials globally would require research into mechanisms that are feasible even in low-resource settings.

Recognising the crucial role of R&D in the areas of vaccination, diagnosis, and treatment, the agenda calls for enhanced efforts to develop new agents against extended-spectrum β -lactamase-producing or carbapenem-resistant Enterobacterales or both, as well as against sexually transmitted infections. The agenda emphasises the need to continue investing in product-related R&D and to expand funding support across the entire research spectrum, from descriptive studies to delivery, development, and discovery.

Drug-resistant tuberculosis

Seven research priorities address the need for improved tools to prevent, diagnose, and treat drug-resistant tuberculosis. These priorities are consistent with the evidence gaps identified in the consolidated guidelines on tuberculosis put forth by the Guidelines Development Groups of WHO^{43,44} and relate to the discovery and development of effective vaccines; more effective, safer, and shorter regimens to treat all forms of drug-resistant tuberculosis; prevention of infection among clinically susceptible individuals; and development of point-of-care tests to detect tuberculosis.

Implications of the research agenda for policy

This paper describes the first WHO research agenda setting global research priorities for AMR in human health, relevant to drug-resistant bacterial and fungal infections of

www.thelancet.com/microbe Vol 5 November 2024

crucial importance for AMR, including drug-resistant *M tuberculosis*. These research priorities encompass the complete people-centred journey, from prevention to diagnosis and treatment, and address overarching knowledge gaps in AMR epidemiology, burden and drivers, policies and regulations, and awareness and education, with a focus on low-resource settings and socioeconomically or clinically vulnerable populations.

The agenda is expected to guide policy makers, the global research community, industry, and research funders in converging research efforts and investments on the most crucial global knowledge gaps. An essential criterion for prioritisation was the potential for translation of research outputs into policy, such that a pronounced effect on AMR prevention practices; the diagnosis, treatment, and management of infections; and national and global policies aiming to mitigate AMR is seen on addressing the research priorities.

The agenda will be instrumental in advancing the discussions and initiatives related to AMR at the UN General Assembly, ensuring that crucial knowledge gaps are addressed by the year 2030 and contributing to national and global strategies for AMR containment and management. Furthermore, evidence⁴⁵ from well designed, large-scale, multidisciplinary studies on the drug-resistant tuberculosis research priorities will support the achievement of the ambitious declarations of the WHO member states to expand coverage of rapid diagnostic testing, treatment, and tuberculosis-preventive treatment to reach 90% and coverage of health and social benefits packages for people with tuberculosis to reach 100% by the year 2027.

Investments in AMR research to date have been inconsistent.³⁸ Between January, 2017, and September, 2021, the Global AMR R&D Hub reported a total investment of US\$ 8.9 billion across 12 093 projects in the field of AMR by 214 organisations worldwide.⁴⁶ Approximately one-third of the investment in priority bacterial pathogens (equivalent to \$4.3 billion) was allocated towards development of novel therapeutics. By contrast, only \$530 million (12%) was designated for vaccines, \$261 million (6%) for diagnostics, and \$32 million (1%) for policy research. In addition, research on fungal infections across all sectors attracted only \$512 million (6%) of all investments. Although still lower than that for other disease areas, \$8.1 billion (90%) of the investments are directed towards R&D targeting bacterial pathogens, with the top research areas in terms of funding volume across all sectors being basic research and therapeutics R&D.46 Investment in product-related R&D such as diagnostics and vaccines is lagging.

Concerted efforts to implement this research agenda have the potential to ensure a more balanced approach to AMR research funding—ie, one that is focused on developing not only an arsenal of therapeutic options but also tools to promptly and accurately diagnose infections and generate evidence for policy makers on the most cost-effective prevention and antimicrobial stewardship interventions, on how interventions should be implemented, and on policies that are also feasible in low-resource settings.

Alignment with and complementarity to other AMR research agendas

In developing this research agenda, we collaborated with other relevant research initiatives to ensure complementarity and alignment, in addition to outlining in more detail the population, intervention or exposure, context, and comparator of interest, wherever possible. The One Health AMR research agenda was codeveloped by the Quadripartite²¹ comprising Food and Agriculture Organization, UN Environment Programme, WHO, and World Organisation for Animal Health, with the aim to improve knowledge on the intricate interactions of AMR among humans, animals, plants, and their shared environment. The WHO research agenda for AMR in human health includes crucial knowledge gaps that do not fall within the scope of the One Health agenda concerning the epidemiology, burden, and drivers of drug-resistant bacterial and fungal infections in the human health sector. The agenda also emphasises the development of optimised diagnostics and antimicrobial treatment strategies. The Strategic Research and Innovation research agenda from the future European Partnership on One Health AMR, co-funded by the member states and the European Commission under the Horizon Europe funding programme, is expected to guide future investments on AMR on topics encompassing both the One Health continuum and human health.⁴⁷ Finally, this agenda aligns with the evidence gaps and needs identified by guideline development groups in the consolidated WHO guidelines on tuberculosis.43,44

Strengths and limitations

We followed a transparent, reproducible, rigorous, and inclusive process.48 The metric-based CHNRI prioritysetting approach minimised the potential bias stemming from the influence of a few individuals, a limitation commonly associated with consensus-based approaches.²³ With the overall participation of 261 individuals from 69 countries (156 experts contributing to survey 1 and 234 experts contributing to survey 2), the agenda reflects a wide range of AMR expertise, geographical diversity, and representativeness, ensuring external relevance and validity of the outcomes. Yoshida and colleagues49 found that a sample size of 45-55 independent experts assigning a score on each question can ensure high reproducibility of the prioritisation results. Our study, with over 100 independent experts assigning a score on each topic, exceeded that threshold. Notably 40% offered perspectives exclusively from lowresource settings, underscoring the agenda's attention to research topics pertinent to LMICs. By supplementing the list of topics identified by experts with a comprehensive scoping review spanning a 10-year period and capturing knowledge gaps in the existing literature, we are confident that we have included the most important topics and that

those prioritised received strong agreement among experts. Notably, 74% of the 175 topics received an RPS of 0.80 or higher across all scoring criteria, affirming the validity of our approach. The research priorities included in the final list are broad and comprehensive. The research priorities effectively balance high-level concepts that capture the essence of multiple, sometimes overlapping, knowledge gaps and the more granular, focused research questions that could be used to design a study. Ultimately, each priority will require multiple studies of various types to be fully addressed, with potential variations based on country or setting.

Nonetheless, our project has some limitations. First, as experts were identified on the basis of their publication records, individuals from the WHO European region and region of the Americas were over-represented compared with those from other regions, reflecting a stronger investment in academic research in these two WHO regions. Second, assigning scores on research topics was tedious for the experts, as noted by some during the survey. Encouragingly, we did not observe a reduction in the number of experts participating in the scoring for topics included in the later part of the survey, suggesting that any potential survey fatigue did not negatively affect the results (data not shown). Third, the numbers of experts and topics varied across different AMR areas, which might have affected the final count of top research priorities in each area. However, simple scatter plots and correlation analyses did not show any obvious strong correlations between the number of participating experts for a given research topic in each AMR area and the final number of research topics from that AMR area in the 40 priorities (data not shown). In fact, experts were encouraged to assign scores on all topics they had knowledge of, without limiting themselves to their primary area of research expertise. Fourth, the scope of the agenda encompassed the WHO list of priority pathogens⁴ and therefore did not account for newly added6 and emerging pathogens and resistance mechanisms, some of which could be specific to the setting. Finally, developing a research agenda is, by its nature, a prioritisation exercise, resulting in only a subset of topics receiving the highest score. Many arguably important topics-although not feasible or prioritised within the proposed 2030 timeframestill merit attention (appendix p 5). Examples include topics related to the effect of climate change on AMR in human health, determining the thresholds for clearing of colonisation by multidrug-resistant pathogens, and understanding the role of social norms (such as gender) in AMR awareness and individual and collective behaviour.24,50-52

Implementation of the research agenda

WHO is committed to supporting the implementation of this agenda by focusing awareness around the 40 research priorities and fostering partnerships and collaboration with research funders and the global research community in the human health sector, including academia; partners such as WHO's AMR collaborating centres network,⁵³ Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator,⁵⁴ FIND,55 Global Antibiotic Research & Development Partnership,56 Global AMR R&D Hub,46 Global Strategy Lab's The International Network for AMR Social Science,57 International Centre for Antimicrobial Resistance Solutions,58 and ReAct59; organisations such as the African Society for Laboratory Medicine, American Society for Microbiology, European Society of Clinical Microbiology and Infectious Diseases; funders and implementing partners including the AMR Action Fund, Bill & Melinda Gates Foundation, Centers for Disease Control and Prevention, European Commission-funded Joint programming initiative on AMR, Fleming Fund, Global Fund, National Institutions of Health, One Health Trust, Unitaid, Wellcome Trust, and World Bank; as well as governments.¹⁰ We urge all stakeholders to intensify investments and initiatives in AMR research, aligned with the priorities of the research agenda. A monitoring and evaluation framework will enable periodic assessment of the agenda's effects in raising awareness, driving implementation, and seeking and influencing funding allocation.

Conclusions

The WHO research agenda for AMR in human health comprises 40 research priorities that hold the potential to invigorate research efforts, generate evidence to improve existing treatment and diagnostic approaches, bolster the implementation of evidence-based national action plans for AMR, and ensure the feasibility of AMR interventions in low-resource settings. The research priorities reflect the most crucial knowledge gaps on AMR in human health that need to be addressed in the medium-to-long-term future (ie, by the year 2030) and aim to guide and encourage scientific interest and investment, generate evidence-based interventions to inform global and national health policies, and ultimately counteract the rise of AMR and its associated morbidity and mortality.

Contributors

SBe in collaboration with ACa led the conceptualisation of the project, with crucial inputs from ZD, RLH, and SBu. ZD, RLH, SBu, IDO, DD, CMC, BDH, NG, MH-A, BA, HS, TW, KUK, and VI compiled and consolidated the knowledge gaps into thematic research topics. SBu and ACh performed the data analysis and visualisation, with input from SBe, ZD, RLH, IDO, DD, and CMC. SBe, ZD, RLH, IDO, DD, and CMC. SBe, ZD, RLH, IDO, DD, and CMC wrote the manuscript, with input from ACa, ACh, KVW, HHB, NG, MH-A, BDH, BA, TW, HS, VI, and KUK. SBe, ACh, SBu, ZD, and CMC had full access to all data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. All primary authors critically reviewed the manuscript for important intellectual content and all authors gave final approval for this version to be published. The collaborators for the WHO research agenda for AMR in human health contributed by identifying knowledge gaps, assigning scores to the research topics, and reviewing the final agenda.

Declaration of interests

SBe, ZD, CMC, HHB, NG, MH-A, BA, HS, TW, BDH, and VI are WHO employees. KVW and ACa were WHO employees. KUK and SBu are WHO consultants. ACh, DD, RLH, and IDO were WHO consultants. RLH is also supported by the Wellcome Trust (106680/Z/14/Z). All authors declare no other competing interests. Declarations of competing interests of the collaborators for the WHO research agenda for AMR in human health were reviewed and are available upon request to the corresponding author.

Acknowledgments

This work is part of the project entitled Global Research Agenda for Antimicrobial Resistance in the Human Health Sector, initiated and funded by the WHO Antimicrobial Resistance Division, through grants from the Kingdom of Saudi Arabia and Centers for Disease Control and Prevention. WHO funded the study and was responsible for study design, data collection, data analysis, data interpretation, and writing of the report. We acknowledge the contributions of Anand Balachandran, Carmem L Pessoa-Silva, Daniel Marcano Zamora, Danilo Lo Fo Wong, Maarten van der Heijden, Kevin Outterson, Zarir Udwadia, Mimi Melles-Brewer, Philip Matthew, Pilar Ramon-Pardo, Robert F Terry, Benjamin Blumel, Sergev Eremin, Simone Moraes Raszl, Stephan Paul Jost, Thomas Joseph, Yahaya Ali Ahmed, Sarah Paulin-Deschenaux, and Palmira Immordino. We also thank Alice Tamara, Gilbert Lazarus, and Fiona Emdin for assistance in the data collection, and David Moore for additional input on the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of WHO or any of the institutions mentioned.

Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

References

- Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022; 399: 629–55.
- 2 The Lancet. Antimicrobial resistance: an agenda for all. Lancet 2024; 403: 2349.
- 3 WHO. Global action plan on antimicrobial resistance. Geneva: World Health Organization; Jan 1, 2016. https://iris.who.int/ handle/10665/253236 (accessed Nov 17, 2023).
- 4 WHO. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; Sept 4, 2017. https://www.who.int/publications/i/ item/WHO-EMP-IAU-2017.12 (accessed Nov 19, 2023).
- 5 WHO. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; Oct 25, 2022. https://apps.who.int/iris/handle/ 10665/363682 (accessed Nov 13, 2023).
- 6 WHO. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; May 17, 2024. https://iris.who.int/handle/10665/376776 (accessed May 30, 2024).
- 7 WHO. Analysis of the antibacterial pipeline. https://www.who.int/ observatories/global-observatory-on-health-research-anddevelopment/analyses-and-syntheses/antimicrobial-resistance/ analysis-of-the-antibacterial-pipeline (accessed Nov 15, 2023).
- 8 WHO, Food and Agriculture Organization of the UN, World Organisation for Animal Health. Monitoring global progress on antimicrobial resistance: tripartite AMR country self-assessment survey (TrACSS) 2019–2020: global analysis report. Geneva: World Health Organization; March 19, 2021. https://iris.who.int/handle/ 10665/340236 (accessed May 30, 2024).
- 9 WHO. Seventy-seventh World Health Assembly provisional agenda item 11.8 Antimicrobial resistance: accelerating national and global responses. April 11, 2024. https://apps.who.int/gb/ebwha/pdf_files/ EB154/B154_13-en.pdf (accessed June 6, 2024).
- 10 WHO. Seventy-seventh World Health Assembly agenda item 11.8 Antimicrobial resistance: accelerating national and global responses. May 28, 2024. https://apps.who.int/gb/ebwha/pdf_files/WHA77/ A77_ACONF1-en.pdf (accessed June 6, 2024).
- 11 WHO. Seventy-seventh World Health Assembly daily update. May 30, 2024. https://www.who.int/news/item/30-05-2024-seventyseventh-world-health-assembly—daily-update-30-may-2024 (accessed June 6, 2024).
- 12 Rudan I. Setting health research priorities using the CHNRI method: IV. Key conceptual advances. J Glob Health 2016; 6: 010501.

- 13 Rudan I, Gibson JL, Ameratunga S, et al. Setting priorities in global child health research investments: guidelines for implementation of CHNRI method. *Croat Med J* 2008; 49: 720–33.
- 14 Vekemans J, Hasso-Agopsowicz M, Kang G, et al. Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a World Health Organization action framework. *Clin Infect Dis* 2021; 73: e1011–17.
- 15 Bulteel AJB, Larson EL, Getahun H. Identifying global research gaps to mitigate antimicrobial resistance: a scoping review. *Am J Infect Control* 2021; **49**: 818–24.
- 16 WHO. Containing antimicrobial resistance: review of the literature and report of a WHO workshop on the development of a global strategy for the containment of antimicrobial resistance. Geneva: World Health Organization; Feb 4–5, 1999. https://iris.who.int/ bitstream/handle/10665/66157/WHO_CDS_CSR_DRS_99.2.pdf (accessed Nov 17, 2023).
- 17 Lacotte Y, Årdal C, Ploy MC. Infection prevention and control research priorities: what do we need to combat healthcare-associated infections and antimicrobial resistance? Results of a narrative literature review and survey analysis. *Antimicrob Resist Infect Control* 2020; 9: 142.
- 18 Rogers Van Katwyk S, Grimshaw JM, Nkangu M, et al. Government policy interventions to reduce human antimicrobial use: a systematic review and evidence map. *PLoS Med* 2019; 16: e1002819.
- 19 Mitnick CD, Rodriguez CA, Hatton ML, et al. Programmatic management of drug-resistant tuberculosis: an updated research agenda. *PLoS One* 2016; 11: e0155968.
- 20 WHO. WHO research agenda for hand hygiene in health care 2023–2030: summary. Geneva: World Health Organization; May 5, 2023. https://iris.who.int/handle/10665/367527 (accessed Nov 15, 2023).
- 21 WHO, FAO, UNEP, WOAH, A One Health priority research agenda for antimicrobial resistance. Geneva: World Health Organization; July 3, 2023. https://apps.who.int/iris/handle/10665/370279 (accessed Nov 17, 2023).
- 22 Knight GM, Raviglione MC, White RG. No antimicrobial resistance research agenda without tuberculosis. *Lancet Glob Health* 2020; 8: e987–88.
- 23 WHO. A systematic approach for undertaking a research prioritysetting exercise: guidance for WHO staff. Geneva: World Health Organization; Sept 23, 2020. https://iris.who.int/handle/10665/ 334408 (accessed Nov 17, 2023).
- 24 Styczynski A, Herzig C, Luvsansharav UO, McDonald LC, Smith RM. Using colonization to understand the burden of antimicrobial resistance across low- and middle-income countries. *Clin Infect Dis* 2023; 77 (suppl 1): S70–74.
- 25 Hamers RL, Dobreva Z, Cassini A, et al. Global knowledge gaps on antimicrobial resistance in the human health sector: a scoping review. Int J Infect Dis 2023; 134: 142–49.
- 26 Hamers RL, Cassini A, Asadinia KS, Bertagnolio S. Developing a priority global research agenda for antimicrobial resistance in the human health sector: protocol for a scoping review. *BMJ Open* 2022; 12: e060553.
- 27 WHO. People-centred approach to addressing antimicrobial resistance in human health: WHO core package of interventions to support national action plans. Geneva: World Health Organization; Oct 19, 2023. https://iris.who.int/handle/10665/373458 (accessed Nov 15, 2023).
- 28 WHO. Global antimicrobial resistance (AMR) research agenda in human health: a call for expert contributions. Oct 14, 2022. https://www.who.int/news-room/articles-detail/global-antimicrobialresistance-research-agenda-in-human-health-a-call-for-expertcontributions (accessed Oct 2, 2023).
- 29 WHO. The WHO AWaRe (access, watch, reserve) antibiotic book. Dec 9, 2022. https://apps.who.int/iris/handle/10665/365237 (accessed Nov 17, 2023).
- 30 Fleming KA, Horton S, Wilson ML, et al. The *Lancet* Commission on diagnostics: transforming access to diagnostics. *Lancet* 2021; 398: 1997–2050.
- 31 Denning DW, Perlin DS, Muldoon EG, et al. Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities. *Emerg Infact Dis* 2017; 23: 177–83.

- 32 Thomson KM, Dyer C, Liu F, et al. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). *Lancet Infect Dis* 2021; 21: 1677–88.
- 33 Charani E, Mendelson M, Pallett SJC, et al. An analysis of existing national action plans for antimicrobial resistance—gaps and opportunities in strategies optimising antibiotic use in human populations. *Lancet Glob Health* 2023; 11: e466–74.
- 34 Patel J, Harant A, Fernandes G, et al. Measuring the global response to antimicrobial resistance, 2020–21: a systematic governance analysis of 114 countries. *Lancet Infect Dis* 2023; 23: 706–18.
- 35 Organisation for Economic Co-operation and Development. Embracing a One Health framework to fight antimicrobial resistance. Sept 14, 2023. https://www.oecd.org/health/Embracing-a-One-Health-Framework-to-Fight-Antimicrobial-Resistance-Brief.pdf (accessed Nov 17, 2023).
- 36 Organisation for Economic Co-operation and Development. Stemming the superbug tide: just a few dollars more. Nov 7, 2018. https://www.oecd.org/health/stemming-the-superbug-tide-97892643 07599-en.htm (accessed Nov 17, 2023).
- 37 The World Bank. Drug-resistant infections: a threat to our economic future. vol. 2: Final Report; March 1, 2017. http://documents. worldbank.org/curated/en/323311493396993758/final-report (accessed May 29, 2023).
- 38 Global AMR R&D Hub, WHO. Incentivising the development of new antibacterial treatments. 2023. https://globalamr.e-laborat.eu/ wp-content/uploads/2023/08/2.-G7_FULLReport_HUB_WHO_ FINAL_10052023.pdf (accessed Oct 2, 2023).
- 39 WHO. 2021 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; May 27, 2022. https://iris.who.int/handle/ 10665/354545 (accessed Nov 15, 2023).
- 40 Årdal C, Røttingen JA, Opalska A, Van Hengel AJ, Larsen J. Pull incentives for antibacterial drug development: an analysis by the transatlantic task force on antimicrobial resistance. *Clin Infect Dis* 2017; 65: 1378–82.
- 41 Outterson K, Rex JH. Global pull incentives for better antibacterials: the UK leads the way. Appl Health Econ Health Policy 2023; 21: 361–64.
- 42 Årdal C, Lacotte Y, Ploy MC. Financing pull mechanisms for antibiotic-related innovation: opportunities for Europe. *Clin Infect Dis* 2020; 71: 1994–99.
- 43 WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. March 20, 2022. Geneva: World Health Organization; 2019. https://iris.who.int/handle/10665/311389 (accessed Nov 15, 2023).
- 44 Global Tuberculosis Programme. Consolidated guidelines. https://tbksp.org/en/guidance-books-solr (accessed Oct 6, 2023).
- 45 UN. Political declaration of the high-level meeting on the fight against tuberculosis: draft resolution. New York: UN; Sept 25, 2023. https://digitallibrary.un.org/record/4022582?ln=en&v=pdf (accessed May 30, 2024).

- 46 Global AMR R&D Hub, Annual Report 2021: the global AMR R&D funding landscape, December, 2021. https://globalamrhub.org/ wp-content/uploads/2024/02/Annual-Report_Final_10122021.pdf (accessed March 19, 2024).
- 17 European Partnership on One Health Antimicrobial Resistance: Strategic research and innovation agenda. 2024. https://www.jpiamr. eu/app/uploads/2024/05/OHAMR-SRIA_draft_20240502.pdf (accessed May 30, 2024).
- 48 Tong A, Synnot A, Crowe S, et al. Reporting guideline for priority setting of health research (REPRISE). BMC Med Res Methodol 2019; 19: 243.
- 49 Yoshida S, Martines J, Lawn JE, et al. Setting research priorities to improve global newborn health and prevent stillbirths by 2025. *J Glob Health* 2016; 6: 010508.
- 50 Magnano San Lio R, Favara G, Maugeri A, Barchitta M, Agodi A. How antimicrobial resistance is linked to climate change: an overview of two intertwined global challenges. *Int J Environ Res Public Health* 2023; 20: 1681.
- 51 Gautron JMC, Tu Thanh G, Barasa V, Voltolina G. Using intersectionality to study gender and antimicrobial resistance in low- and middle-income countries. *Health Policy Plan* 2023; 38: 1017–32.
- 52 WHO. Incorporating intersectional gender analysis into research on infectious diseases of poverty - a toolkit for health researchers. Geneva: World Health Organization; Sept 15, 2020. https://iris.who. int/handle/10665/334355 (accessed March 8, 2023).
- 53 WHO. WHO AMR surveillance and quality assessment collaborating centres network. 2023. https://www.who.int/initiatives/glass/ network (accessed Oct 18, 2023).
- 54 CARB-X. Annual report 2021–2022: working together to address the global threat of antimicrobial resistance. 2023. https://carb-x.org/ wp-content/uploads/2023/05/2023-0502-CARBX-annual-reportcombined-sm.pdf (accessed Oct 18, 2023).
- 55 FIND. AMR test directory. 2023. https://www.finddx.org/tools-and-resources/dxconnect/test-directories/amr-test-directory/ (accessed Oct 18, 2023).
- 56 Global Antibiotic Research & Development Partnership. Annual Report 2022. Confronting the scale of antibiotic resistance. 2022. https://gardp.org/wp-content/uploads/2023/06/GARDP-Annual-Report-2022.pdf (accessed Oct 18, 2023).
- 57 The International Network for AMR Social Science. 2022 INAMRSS Workshop Statement. Oct 6, 2022. https://www.globalstrategylab. org/wp-content/uploads/2023/08/INAMRSSStatement2022-10-07-1. pdf (accessed Oct 18, 2023).
- 58 International Centre for Antimicrobial Resistance Solutions. ICARS strategy: 2022–2026. July 30, 2022. https://icars-global.org/ wp-content/uploads/2022/08/ICARS-Strategy-2022_spreads.pdf (accessed Oct 18, 2023).
- 59 ReAct. Public health driven innovation & access to antibiotics & diagnostics. https://www.reactgroup.org/about-us/public-healthdriven-innovation/ (accessed Oct 18, 2023).

© 2024 Published by Elsevier Ltd. This is an open access article under the CC BY IGO license (http://creativecommons.org/licenses/by/3.0/igo/).